Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Rises By 816.4%

Posted by Jeff Wilder on Jul 12th, 2026

Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report) was the recipient of a large increase in short interest in June. As of June 30th, there was short interest totaling 91,267 shares, an increase of 816.4% from the June 15th total of 9,959 shares. Based on an average daily trading volume, of 194,642 shares, the short-interest ratio is currently 0.5 days. Approximately 2.5% of the shares of the company are sold short.

Pulmatrix Stock Down 4.4%

PULM stock traded down $0.08 during trading on Friday, reaching $1.72. The company’s stock had a trading volume of 46,122 shares, compared to its average volume of 110,484. Pulmatrix has a 1 year low of $1.16 and a 1 year high of $6.83. The company has a market capitalization of $6.28 million, a P/E ratio of -1.40 and a beta of 1.90. The company’s fifty day moving average is $1.45 and its 200-day moving average is $1.88.

Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Pulmatrix in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Pulmatrix presently has a consensus rating of “Sell”.

View Our Latest Stock Report on Pulmatrix

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Pulmatrix stock. DRW Securities LLC purchased a new position in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. 11.84% of the stock is owned by institutional investors and hedge funds.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).